with unrivaled sensitivity
Despite significant progress in protein detection technologies over the past fifty years, much of the human plasma proteome remains undetectable by existing technologies. This limitation is due to the tradeoffs made by current proteomic analysis methods, which sacrifice either depth (sensitivity and dynamic range) or breadth (multiplex).
With Alamar’s innovative NULISA™ technology, this long-standing challenge has finally been overcome. With the ability to deeply interrogate the proteome at attomolar sensitivity, even low-abundance proteins can now be detected.
Additionally, NULISA™ allows for the simultaneous measurement of changes in hundreds to thousands of proteins from a single sample, providing a breadth of data previously unattainable by existing technologies. This breakthrough is set to revolutionize our understanding of the human proteome and its role in health and disease.
A PARADIGM SHIFT
With unprecedented sensitivity, high multiplexing, and a fully automated workflow, NULISA provides researchers with the power to profile and validate clinically relevant biomarkers for translation from discovery to the clinic.
Our precision proteomics platform will transform the early detection and treatment of disease by unlocking the promise of ultra-sensitive liquid biopsy assays.
Enables detection and quantification of low abundance proteins leading to the discovery and validation of critical new biomarkers
Supports quantification across a broad range of biological expression levels without dilution
Provides ability to focus on a single target or multiplex
100s to 1000s of targets in
a single experiment
Offers ease of use and minimal hands-on time reducing the need for technical expertise
The ARGO™ System is a fully automated, high-throughput precision proteomics platform for ultra-high sensitivity analysis across a range of multiplex levels to support broad biomarker profiling and translation of validated biomarkers into clinical use.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.